Whether Midostaurin has been included in the 2025 medical insurance and reimbursement policy

Currently Midostaurin has not yet been officially approved for marketing by the national drug regulatory authorities (such as National Medical Products Administration) in mainland China. As of now, midostaurin is not yet available in mainland China. Therefore, there is no domestic legal marketing channel for midostaurin, and there is no domestic medical insurance (medical insurance) inclusion or reimbursement policy support. In other words, even if the drug is obtained through formal overseas channels, it cannot be reimbursed through domestic medical insurance.

Since it is not on the market in China, if patients really need to use midostaurin, they must obtain it through "regular overseas channels". The price range of overseas original research versions of midostaurin (such as the European version, Indian version, and Turkish version) ranges from 20,000 to more than 120,000 yuan. It is said that there is a officially launched "imitation version" of midostaurin in the Indian market. Its pharmaceutical ingredients are basically the same as those of the original research. The specifications are 25 mg×28 tablets. The latest price is about 9,000 yuan. Although these channels are legal national drugs, they face multiple and complex procedures such as import, inspection, filing, taxes, and logistics when used domestically, and medical insurance does not support reimbursement.

Because midostaurin has not yet been marketed in China, it is not included in the domestic medical insurance directory. Even if patients obtain drugs through self-importation, they usually have to bear the cost themselves and do not enjoy national or local medical insurance subsidies. In addition, there are no specific documents or guidelines officially issued by China regarding the domestic reimbursement policy for midostaurin. Therefore, patients should conduct a full economic and legal risk assessment before use. It is recommended that patients communicate with the attending physician, hospital pharmacy department and medical insurance department to clarify the prerequisites and possible medical risks of "importing drugs at their own expense + the legality of domestic use".

For patients who are considering using midostaurin, they should focus on the following points: First, confirm whether they are suitable for the drug (such as acute myeloid leukemia with FLT3 mutation, etc.) and Treat under the guidance of an experienced hematologist; secondly, assess the financial burden and the legality of overseas procurement channels to ensure the authenticity of the source of the drug and compliance with logistics; thirdly, make it clear that domestic reimbursement through medical insurance is not currently available, and the costs involved need to be borne by yourself; finally, pay close attention to future regulatory developments. If midostaurin is approved in China and included in medical insurance in the future, patient reimbursement rates, payment methods and accessibility will be significantly improved.

Reference materials:https://www.drugs.com/